Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $682.16M | $556.38M | $1.60B | $197.58M | $22.39M | $18.66M | $34.29M | $31.18M |
| Cost of Revenue | $202.74M | $343.77M | $902.64M | N/A | N/A | $113.84M | N/A | N/A |
| Gross Profit | $479.42M | $212.61M | $696.31M | $197.58M | $22.39M | $-95.18M | $34.29M | $31.18M |
| Gross Margin | 70.28% | 38.21% | 43.55% | 100.00% | 100.00% | -510.02% | 100.00% | 100.00% |
| Operating Expenses | $728.35M | $779.13M | $1.34B | $1.88B | $439.11M | $25.40M | $208.21M | $202.89M |
| Operating Income | $-248.93M | $-566.51M | $-644.74M | $-1.69B | $-416.72M | $-120.58M | $-173.92M | $-171.71M |
| Operating Margin | -36.49% | -101.82% | -40.32% | -853.61% | -1861.35% | -646.13% | -507.23% | -550.78% |
| Net Income | $-187.50M | $-545.06M | $-657.94M | $-1.74B | $-418.26M | $-130.10M | $-184.75M | $-183.77M |
| Net Margin | -27.49% | -97.97% | -41.15% | -882.55% | -1868.23% | -697.15% | -538.81% | -589.46% |
| EPS (Basic) | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.43 | $-5.40 | $-9.99 | $-12.56 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |